Medication Adherence Measures

Mastering Medication Adherence Measures in 2026 MA Stars

Mastering Medication Adherence Measures in 2026 MA Stars

In Medicare Advantage, few measures have historically carried as much weight—literally and figuratively—as the Medication Adherence measures. These three pharmacy-based metrics, focused on diabetes, hypertension, and cholesterol medications, have long been triple-weighted in the CMS Star Ratings program and together represent one of the largest single influences on a plan’s overall performance score.

For the 2026 measurement year, however, CMS implemented substantive specification updates to the Medication Adherence measures, including the addition of sociodemographic status (SDS) risk adjustment. As a result of these lasting methodology changes, CMS temporarily reduced the weight of the measures to single weight for 2026, with the expectation that they will return to triple weighting in 2027 once the updated specifications are fully established.

At their core, these measures track how consistently patients take their long-term maintenance medications throughout the year. They use a calculation known as the Proportion of Days Covered (PDC), which estimates the percentage of days a patient has medication available based on prescription refill data. A PDC of 80% or higher indicates adherence—an important threshold for maintaining control of chronic conditions and achieving high Star Ratings.

For plans and providers, medication adherence is more than a data point—it’s a window into patient behavior, system design, and care coordination. The challenge? Adherence rates often start strong early in the year but tend to dip by late summer and fall, as refill gaps accumulate and more members fall below the 80% mark. Understanding this pattern is key to keeping patients adherent and preserving performance through year-end.

In this article, we’ll break down how the Medication Adherence measures work, what makes the PDC methodology so influential, the latest 2026 CMS cut points, and actionable strategies that healthcare teams can use to stay ahead—because in today’s Medicare Advantage landscape, these three triple-weighted measures can make or break a contract year.

Medication Adherence Measures - MA Stars

Why Medication Adherence Measures Matter in Medicare Advantage

Medication adherence is one of the most powerful levers in the CMS Star Ratings program. Each of the three adherence measures—covering diabetes medications, blood pressure medications (RAS antagonists), and statins for cholesterol—has historically been triple weighted, meaning each carried three times the influence of most other quality measures.

For the 2026 measurement year, these measures are single weighted, not due to reduced importance, but because CMS implemented lasting specification changes—most notably SDS risk adjustment—requiring a transitional weighting period. CMS has indicated that the Medication Adherence measures are expected to return to triple weighting in 2027, reinforcing their long-term role as a cornerstone of Star Ratings performance.

The Power of Triple Weighting

CMS assigns higher weighting to measures that are closely tied to patient outcomes and long-term health management. Medication adherence directly affects chronic condition control, hospitalizations, and mortality—making it both a clinical and financial priority. Because of this, a one- or two-point change in adherence performance can have an outsized impact on plan revenue, quality bonus payments, and competitive positioning.

Why the Measures Were Single Weighted in 2026

Beginning with the 2026 measurement year (2028 Star Ratings), CMS implemented substantive specification updates to all three Medication Adherence measures. The most notable change is the addition of sociodemographic status (SDS) risk adjustment, which adjusts measure performance based on patient characteristics such as age, gender, low-income subsidy or dual eligibility status, and disability status. These updates align the measures more closely with Pharmacy Quality Alliance (PQA)–endorsed specifications and reflect CMS’s broader effort to more appropriately account for differences in patient populations.

In addition to SDS risk adjustment, CMS also finalized non-substantive but operationally meaningful specification changes, including:

  • Updates to continuous enrollment (CE) criteria to fully align with PQA specifications, and

  • Removal of the inpatient (IP) and skilled nursing facility (SNF) stay adjustments, which previously credited adherence days during facility stays.

Together, these changes alter how adherence is calculated and monitored at the member level, even though the underlying PDC ≥80% adherence threshold remains unchanged.

Because SDS risk adjustment represents a meaningful methodological change, CMS designated the Medication Adherence measures as single weighted for MY2026, consistent with how measures are treated during periods of specification transition. CMS has indicated that the measures are expected to return to triple weighting in MY2027, once the updated methodology has stabilized.

How Adherence Impacts Both Quality and Revenue

When patients maintain consistent medication use, their chronic conditions—like diabetes, hypertension, and hyperlipidemia—stay better controlled. That leads to fewer emergency department visits, fewer hospitalizations, and better HEDIS outcomes on related measures such as blood pressure control and diabetes A1c.

For payers and providers in value-based arrangements, the implications extend even further:

  • Higher Star Ratings mean larger quality bonus payments and more resources for care coordination.
  • Improved risk adjustment accuracy, as consistent medication fills help confirm active chronic conditions.
  • Lower total cost of care, driven by reduced acute utilization.
  • Better patient satisfaction, since proactive refill support and follow-up often correlate with higher CAHPS scores.

In other words, success in Medication Adherence measures isn’t only about pharmacy claims—it’s about connecting clinical performance, patient engagement, and financial sustainability.

Breaking Down the Three Adherence Measures

The Medication Adherence measures in Medicare Advantage evaluate whether patients consistently fill and take medications for diabetes, hypertension, and cholesterol management. All three are based on prescription refill behavior captured through Prescription Drug Event (PDE) data submitted by Part D plans to CMS. While historically triple weighted, the measures are single weighted for the 2026 measurement year due to lasting specification updates and are expected to return to triple weighting in 2027.

Each measure is adapted from the Pharmacy Quality Alliance (PQA) Proportion of Days Covered (PDC) methodology, which estimates how many days a patient has medication available within a year. Patients must have at least two prescription fills and be continuously enrolled for a treatment period of at least 91 days.

Let’s look at each measure more closely.

Medication Adherence for Diabetes Medications (D08)

Tracks the percentage of beneficiaries aged 18 and older who maintain a PDC of 80% or higher for oral and non-insulin diabetes therapies such as metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, thiazolidinediones, and meglitinides.

  • Exclusions: Patients using insulin, those with ESRD, or in hospice.
  • 2026 5-Star Cut Point: ≥92%
  • Maintaining adherence for diabetes medications is particularly important because poor adherence leads to loss of glycemic control and increased risk of hospitalizations and complications.

Medication Adherence for Hypertension (RAS Antagonists) (D09)

Measures the percentage of patients prescribed ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or direct renin inhibitors who achieve a PDC of 80% or higher.

  • Exclusions: Hospice, ESRD, or those prescribed sacubitril/valsartan.
  • 2026 5-Star Cut Point: ≥93%
  • Both the 4-star and 5-star thresholds are set in the 90s, leaving very little room for error—small declines can have an outsized effect on a plan’s rating.

Medication Adherence for Cholesterol (Statins) (D10)

Evaluates adherence to statin therapy among adults with at least two fills on unique dates of service. This includes commonly prescribed statins such as atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, and fluvastatin.

  • Exclusions: Hospice, ESRD.
  • 2026 5-Star Cut Point: ≥93%
  • Like the hypertension measure, both 4-star and 5-star cut points for cholesterol adherence sit in the 90% range, meaning even modest lapses in refill timeliness can significantly affect performance. Statin adherence is a cornerstone of cardiovascular prevention, and declines in adherence are common later in the year when patients experience “refill fatigue.”

Each measure is a binary pass/fail outcome at the patient level—once a patient’s PDC falls below 80%, they count as non-adherent for the entire year. That makes early engagement, refill synchronization, and monitoring essential.

Understanding Proportion of Days Covered (PDC)

The Proportion of Days Covered (PDC) is the foundation of all three Medication Adherence measures. It’s a straightforward concept with complex implications: how many days in a year did a patient actually have their medication on hand?

In CMS Stars methodology, the PDC is calculated using prescription fill data from Prescription Drug Event (PDE) files. It measures the percentage of days a patient is “covered” by their medication—either the same drug or another within the same therapeutic class—between the first fill and the end of the measurement period.

Medication Adherence Measures - PDC

 

How PDC Is Calculated

PDC is determined by dividing the number of days the patient had medication available by the total number of days in their treatment period. For example:

  • A patient with 292 days of medication on hand over a 365-day period would have a PDC of 80%, just meeting the adherence threshold.
  • Patients must have at least two fills on unique dates of service and be continuously enrolled for a treatment period of at least 91 days.

The calculation adjusts for overlapping fills (so early refills don’t double-count) and for inpatient or skilled nursing facility stays, during which medications are typically administered by the facility.

Why 80% Is the Key Threshold

The 80% mark isn’t arbitrary. Research validated by the Pharmacy Quality Alliance (PQA) and multiple peer-reviewed studies has shown that adherence rates below 80% correlate with poorer clinical outcomes, higher hospitalization rates, and increased mortality across chronic disease states.

The Late-Year Decline: Why Adherence Rates Drop

Medication adherence rates often look strong in the first half of the year—many patients start with fresh refills in January. But as the year progresses, both the math and mechanics of the measure make sustaining high performance increasingly difficult.

A key factor is how the denominator evolves. Patients are only included in the measure once they have two fills on unique dates of service, but their clock starts earlier—on the date of their first fill, known as the Index Prescription Start Date (IPSD). In other words, a patient may not appear on a denominator list yet, but their adherence period is already underway. If they miss or delay their second fill, they’re quietly accumulating uncovered days that will count against them once they enter the measure population.

This creates a hidden layer of risk early in the year. The most impactable time for intervention is often before a patient even shows up on standard adherence gap lists—making early identification and proactive refill monitoring essential.

Meanwhile, among patients already in the denominator:

  • Delayed refills or therapy changes erode their PDC as uncovered days add up.
  • Hospitalizations or transitions of care can pause fills temporarily, sometimes unnoticed.
  • Seasonal and behavioral factors—from vacation schedules to refill fatigue—compound in the later months.

By Q4, the margin for error is razor-thin. A single 10-day gap can push a patient below the 80% threshold, locking in non-adherence for the year. For this reason, plans and providers that treat adherence as a year-long discipline—not a late-year salvage effort—consistently outperform those reacting to gap lists alone.

2026 Cut Points and Performance Benchmarks

Medication Adherence measures continue to be among the most competitive in the Medicare Advantage Stars program, and the 2026 CMS cut points raise expectations yet again.

Measure

3-Star

4-Star

5-Star

Medication Adherence for Diabetes (MAD)

86%

89%

92%

Medication Adherence for Hypertension (MAH)

88%

91%

93%

Medication Adherence for Cholesterol (MAC)

88%

90%

93%

(Source: CMS— see 2026 CMS Stars Cut Points for the full table and analysis.)

The Shrinking Margin of Error

With 4-star and 5-star thresholds now in the 90s, the difference between high and low performers has narrowed dramatically. In practical terms, a plan maintaining a 91% adherence rate for hypertension or cholesterol could see its measure rating drop an entire star with only a one- or two-point decline.

This razor-thin margin amplifies the importance of timely refill monitoring, cross-functional pharmacy coordination, and member-level precision. Adherence performance is no longer driven by broad program design alone—it depends on the micro-level consistency of individual patient behaviors tracked throughout the year.

The temporary reduction to single weight in 2026 does not materially change the underlying performance risk. Cut points remain tight, member-level failure dynamics are unchanged, and late-year adherence erosion still compounds quickly. Plans that ease adherence focus during 2026 may experience artificial stability, only to face amplified performance and revenue risk when triple weighting resumes in 2027.

Even top-performing plans can see late-year slippage erase earlier gains if refill gaps aren’t caught quickly. Sustaining success at these higher cut points now requires real-time visibility and early intervention models rather than retrospective clean-up at year-end.

Key Strategies to Improve Medication Adherence

Even with single weighting in 2026, adherence strategy should remain unchanged, as the workflows, analytics, and patient behaviors required for success must already be in place before the measures return to triple weighting. Improving performance on the Medication Adherence measures requires both timing and precision. Because the PDC clock starts with the first fill—not when a patient officially enters the denominator—interventions need to begin as early as possible in the measurement year.

Beginning in the 2026 measurement year, CMS also removed prior inpatient and skilled nursing facility day adjustments, further emphasizing the importance of consistent outpatient refill behavior across the full treatment period. What works in January may not be as effective in October, and the most successful Medicare Advantage plans design their adherence strategies around the seasonality of risk rather than late-year recovery.

Early-Year Focus: Laying the Foundation

The first few months of the year set the tone for adherence performance. Once gaps accumulate, there’s little mathematical room to recover. Early actions should emphasize prevention and setup, targeting both new therapy starts and known high-risk members:

  • Identify new therapy starts early. Track first fills to flag patients who may not yet have a second fill. They are “in play” even before appearing on standard adherence lists.
  • Re-engage last year’s non-adherent members. Prior-year performance is one of the strongest predictors of future behavior. Outreach to these patients should start immediately—before refill patterns repeat. Tailored coaching, medication reviews, or simplifying regimens can prevent the same drop-offs from recurring.
  • Encourage 90-day or 100-day fills. Longer supplies minimize refill fatigue and eliminate unnecessary pharmacy trips.
  • Address access barriers upfront. Ask about cost concerns, pharmacy preferences, and transportation needs during the first fill or follow-up visit.
  • Coordinate with prescribers and pharmacies. Ensure prescriptions align with the plan’s formulary and refill timing—dose changes can trigger gaps if not re-sent promptly.

Mid-Year Strategy: Monitor and Reinforce

By mid-year, most patients have established fill patterns. The goal shifts from onboarding to sustainment and recovery:

  • Implement real-time refill alerts. Use PDE or pharmacy claims data to trigger outreach within days of a missed fill.
  • Leverage pharmacy partners. Retail and mail-order pharmacies can help with refill synchronization, adherence packaging, and auto-refill programs.
  • Engage care teams. Embed adherence discussions into care management calls and chronic disease follow-ups.
  • Reinforce medication purpose. Regular reminders of why medications matter—especially for asymptomatic conditions like hypertension or cholesterol—can reduce quiet drop-offs.

Late-Year Strategy: Contain Losses

By Q4, there’s limited time to influence the PDC trajectory. The goal is to minimize attrition among members still in play:

  • Prioritize outreach to “borderline” patients. Those hovering just above 80% PDC are most at risk of slipping below the threshold.
  • Confirm active fills and refill timing. Even minor delays can push adherence below the line.
  • Promote mail-order or extended refills before holidays to prevent travel-related lapses.
  • Engage caregivers and family. For older adults or those on multiple medications, reminders and support systems can help sustain adherence through year-end.

Beyond the Calendar: Build a Continuous Model

The strongest performers view adherence as a year-round, multi-channel effort—not a box to check each measurement year. Continuous adherence programs often include:

  • Predictive analytics to identify members at rising risk before they fall below 80%.
  • Clinical-pharmacy integration to close communication loops between prescribers and dispensing pharmacies.
  • Patient education initiatives that frame adherence as part of self-management and empowerment, not compliance.

Why This Matters for Providers and Patients

Medication adherence isn’t just a metric on a dashboard—it’s one of the most tangible connections between clinical care, patient behavior, and health outcomes. For both providers and patients, consistent adherence delivers measurable benefits that extend well beyond the CMS Star Ratings framework.

For Providers and Health Systems

For provider organizations participating in value-based contracts, the Medication Adherence measures represent an outsized opportunity—and risk. Because these three measures are triple weighted, together they can account for more than a quarter of a plan’s overall Star Rating.

Strong performance translates into:

  • Higher quality bonus payments and shared savings opportunities under Medicare Advantage contracts.
  • Improved overall Star Rating stability, which supports long-term payer relationships and patient retention.
  • Downstream quality gains—since medication adherence directly supports better outcomes on related measures such as diabetes A1c control, blood pressure control, and statin use in cardiovascular disease.
  • Lower medical spend, driven by reduced acute events, hospitalizations, and readmissions.

From an operational standpoint, these measures also drive collaboration across care teams—linking pharmacy, population health, and primary care efforts under a shared goal that’s both clinically meaningful and financially impactful.

For Patients

For patients, adherence is one of the simplest and most effective ways to improve chronic condition management and overall well-being. Staying adherent:

  • Keeps conditions like diabetes, hypertension, and hyperlipidemia under control, preventing complications.
  • Reduces emergency visits and hospitalizations.
  • Enhances quality of life through greater disease stability.

Yet adherence challenges are often not about willingness—they’re about barriers. Cost, transportation, side effects, or simple forgetfulness can all derail medication routines. Addressing these barriers early—through refill synchronization, pharmacy counseling, or care management outreach—helps patients succeed while improving population-level quality outcomes.

In short, adherence represents a rare alignment of incentives: what benefits the patient also benefits the provider, the plan, and the health system as a whole.

Final Takeaways

Medication adherence may appear to be a pharmacy-driven measure, but its influence spans far beyond refill data. While CMS temporarily reduced the weight of these measures in 2026 due to lasting specification updates, their clinical relevance, operational complexity, and future financial impact remain firmly intact.

With 4- and 5-star cut points now hovering around or within the 90s for all three measures—and the gap between them narrowing—the margin for error is minimal. Even small declines in adherence can shift a contract’s overall Star Rating. To stay competitive, organizations must move beyond year-end pushes and adopt continuous, data-driven strategies.

A few guiding principles stand out:

  • Start early. Intervene at or before the first fill—don’t wait for members to appear on adherence reports.
  • Focus on last year’s non-adherents. They remain the most predictable source of lost ground if not re-engaged early.
  • Track continuously. Use real-time or near-real-time data to spot early refill delays before PDC gaps widen.
  • Collaborate across teams. Integrate pharmacy, care management, and provider workflows for consistent outreach.
  • Educate patients continuously. Empower them to understand why adherence matters and how small actions—like filling on time—directly impact their health.

The Medication Adherence measures are among the most competitive in the Stars program, but they’re also among the most controllable when approached strategically. Sustained adherence success depends on year-round vigilance—transforming what’s often seen as a reactive measure into a proactive marker of system-wide quality.

In practice, 2026 should be viewed not as a reprieve, but as a bridge year—an opportunity to strengthen adherence infrastructure ahead of the expected return to triple weighting in 2027.

Resources